MRK - Merck & Co., Inc.
| Previous close | 82.69 |
| Open | 82.70 |
| Bid | 80.71 x 3200 |
| Ask | 82.57 x 800 |
| Day's range | 81.15 - 82.82 |
| 52-week range | 62.38 - 87.07 |
| Volume | 11,501,694 |
| Avg. volume | 10,513,047 |
| Market cap | 209.55B |
| Beta (3Y monthly) | 0.33 |
| PE ratio (TTM) | 25.70 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.20 (2.66%) |
| Ex-dividend date | 2019-06-14 |
| 1y target est | N/A |
- Business Wire•5 days ago
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, 1.25 grams, a new combination antibacterial. RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa. RECARBRIO is also indicated in patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis and Pseudomonas aeruginosa.
- Business Wire•12 days ago
Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019
Data Include Week 48 Results from Phase 2B Study Evaluating MK-8591 in Combination with Doravirine
- Business Wire•13 days ago
FDA Accepts Merck’s Supplemental Biologics License Applications for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule for Melanoma and Multiple Other Indications
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review six supplemental Biologics License Applications to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include an every-six-weeks dosing schedule option.
- Business Wire•21 days ago
Merck to Hold Second-Quarter 2019 Sales and Earnings Conference Call on July 30
Merck (MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 30. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.
- Business Wire•26 days ago
CDC Advisory Committee on Immunization Practices (ACIP) Votes to Provisionally Recommend Shared Clinical Decision-Making for Vaccination of Adults Ages 27-45 with GARDASIL®9 & Harmonization of Catch-up Vaccination for Males and Females Through Age 26
Merck (MRK), known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to recommend HPV vaccination with GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) based on shared clinical decision making for individuals 27 through 45 years of age who are not adequately vaccinated. The ACIP also voted to expand routine and catch-up recommendations for males through 26 years of age who are not adequately vaccinated. The CDC currently recommends routine vaccination of females and males 11-12 years of age, and vaccination can begin at age 9.
- Business Wire•last month
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
At a meeting with the investment community today, Merck (MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term. “Merck is very well positioned to pursue its mission to save and improve lives,” said Kenneth C. Frazier, Merck chairman and chief executive officer.
- Business Wire•last month
AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
LYNPARZA is the Only PARP Inhibitor Approved in Japan
- Business Wire•last month
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Marks First Approval for KEYTRUDA in SCLC
- Business Wire•last month
LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Tri
- Business Wire•last month
FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)
KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose T
- Business Wire•last month
Merck to Acquire Tilos Therapeutics
Merck (MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.
- Business Wire•2 months ago
FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug Application (sNDA) for the use of ZERBAXA® (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens. The sNDA for ZERBAXA had previously been designated Priority Review status by the FDA.
- Business Wire•2 months ago
LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy
AstraZeneca and Merck’s LYNPARZA Increased the Median Time Without Disease Progression or Death by 4.2 Months Versus Physician’s Choice of Chemotherapy Following Two or More Prior
- Business Wire•2 months ago
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
22% of Patients Receiving LYNPARZA Remained Progression-Free After Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy
- Business Wire•2 months ago
Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting
Longest Follow-Up Data for KEYTRUDA in Lung Cancer to Date Showed Five-Year Overall Survival Rate of 23.2% with KEYTRUDA in Treatment-Naïve Patients and 15.5% in Previously Treated
- Business Wire•2 months ago
Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
Survival Benefit Now Observed with KEYTRUDA in Combination with Chemotherapy in All Patient Populations and with KEYTRUDA Monotherapy in Patients W
- Business Wire•2 months ago
Merck Announces Third-Quarter 2019 Dividend
Merck (MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.55 per share of the company’s common stock for the third quarter of 2019. For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.
- Business Wire•2 months ago
Merck Foundation Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings
The Merck Foundation (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation awarded a $1.99 million, five-year grant to ACS to improve support and access to care for people living with cancer in low-and-middle-income countries, particularly in sub-Saharan Africa. This funding will help ACS further develop its capacity development approach to expanding patient navigation to countries with a growing burden of cancer. More than 70% of the 9 million cancer-related deaths worldwide are in resource-limited settings, where patients face many barriers in seeking a timely diagnosis and receiving high-quality cancer care.
- Business Wire•2 months ago
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
Merck (MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).
- Business Wire•2 months ago
Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
Merck , known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy .
- EQS Group•2 months ago
DGAP-DD: Merck KGaA english
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 16.05.2019 / 14:40 The issuer is solely responsible for the content of this announcement. * * *1\. Details of the person discharging managerial responsibilities / person closely associated a) Name Title: First name: Belén Last name(s): Garijo Lopez 2\. Reason for the notification a) Position / status Position: Member of the Executive Board b) Initial notification 3\. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Merck KGaA b) LEI 529900OAREIS0MOPTW25 4\. Details of the transaction(s) a) Description of the financial instrument, type of instrument, identification code Type: Share ISIN: DE0006599905 b) Nature of the transaction Acquisition c) Price(s) and volume(s) Price(s) Volume(s) 90.3964 EUR 135594.60 EUR d) Aggregated information Price Aggregated volume 90.3964 EUR 135594.60 EUR e) Date of the transaction 2019-05-15; UTC+2 f) Place of the transaction Outside a trading venue * * *16.05.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: Merck KGaA Frankfurter Str. 250 64293 Darmstadt Germany Internet: www.merck.de End of News DGAP News Service
- Business Wire•2 months ago
New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting
First-Time Data from POLO Trial Evaluating LYNPARZA® in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program
- Business Wire•2 months ago
Katie Couric Joins Merck and Cancer Advocates to Support Patients and Caregivers Through the Expansion of Your Cancer Game Plan (YCGP)
Merck today announced a collaboration with journalist, author and longtime cancer advocate, Katie Couric, to launch “With Love, Me,” a new feature of Merck’s U.S. patient awareness campaign, Your Cancer Game Plan. Couric will join the program, which showcases a series of heartfelt letters on WithLoveMe.com written by caregivers and cancer survivors to their former selves touching upon what they wished they had known – or needed to hear – when they were first coping with a cancer diagnosis.
- Business Wire•2 months ago
Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants
V114 Met Primary Endpoint by Demonstrating Noninferiority to PCV13 for all Shared Serotypes, and an Immune Response for Two Additional Serotypes